Pfizer Inc. (PFE)

NYSE: PFE · IEX Real-Time Price · USD
52.31
-0.12 (-0.23%)
At close: Jul 1, 2022 4:03 PM
52.28
-0.03 (-0.06%)
After-hours: Jul 1, 2022 7:59 PM EDT
-0.23%
Market Cap 293.51B
Revenue (ttm) 92.37B
Net Income (ttm) 24.97B
Shares Out 5.61B
EPS (ttm) 4.44
PE Ratio 11.78
Forward PE 7.82
Dividend $1.58 (3.02%)
Ex-Dividend Date Jul 28, 2022
Volume 16,091,648
Open 52.04
Previous Close 52.43
Day's Range 51.25 - 52.37
52-Week Range 38.93 - 61.71
Beta 0.71
Analysts Buy
Price Target 59.79 (+14.3%)
Earnings Date Jul 28, 2022

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zit... [Read more...]

Industry Pharmaceuticals
Founded 1849
CEO Albert Bourla
Employees 79,000
Stock Exchange NYSE
Ticker Symbol PFE
Full Company Profile

Financial Performance

In 2021, Pfizer's revenue was $81.29 billion, an increase of 95.16% compared to the previous year's $41.65 billion. Earnings were $21.98 billion, an increase of 139.98%.

Financial Statements

Analyst Forecast

According to 31 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is 59.79, which is an increase of 14.30% from the latest price.

Price Target
$59.79
(14.30% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Pfizer (PFE) Seeks FDA Nod for Its Oral Antiviral COVID Pill

Pfizer (PFE) submits NDA to the FDA seeking approval for using its oral antiviral COVID pill in vaccinated and unvaccinated patients at a high risk of developing severe COVID-19 complications.

FDA Recommends Adding New Omicron Subvariants to COVID Boosters

In anticipation of a new surge of COVID-19 infections later this year, the FDA recommends that COVID-19 vaccine manufacturers develop bivalent booster vaccines that contain the BA.4/BA.5 Omicron subvari...

Other symbols: BNTXMRNA

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

FDA asks vaccine makers to create Covid boosters targeting omicron subvariants

Dr. Scott Gottlieb, former FDA commissioner and CNBC contributor, joins CNBC's 'Squawk Box' to break down the FDA's request to vaccine makers for an updated Covid-19 vaccine and more.

Other symbols: AZNBNTXJNJMRNA

Why Pfizer Popped While the Market Flopped Today

The popularity of the company's coronavirus vaccine is far from waning.

This Analyst Says US Government Buying More COVID-19 Vaccines At Higher Prices

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government. SVB Leerink says that the new contract implies the price per Comirnaty d...

Other symbols: BNTX

US, Pfizer reach $3.2B COVID vaccine deal

Partners Pfizer and BioNTech SE said they had signed a more than $3-billion-dollar agreement with the U.S. government for 105 million doses of their COVID vaccine.

PFE Stock Rises as Pfizer Requests FDA Approval of Covid-19 Treatment Paxlovid

PFE stock is up in afternoon trading as Pfizer enjoys a double round of positive news regarding its Covid-19 drugs. The post PFE Stock Rises as Pfizer Requests FDA Approval of Covid-19 Treatment Paxlovi...

Will Palantir, Pfizer And Oracle Stocks Continue Higher In This Trend?

Oracle Corporation (NYSE: ORCL), Pfizer Inc (NYSE: PFE) and Palantir Technologies Inc (NYSE: PLTR) were all trading near to flat on Thursday in contrast to the S&P 500, which was exhibiting a high level...

Other symbols: ORCLPLTR

Moody's reduces outlook for pharma industry, Pfizer to provide additional COVID vaccine doses

Yahoo Finance's Anjalee Khemlani joins the Live show to discuss Moody's outlook for pharmaceutical industry as well as reports that Pfizer is looking to provide additional COVID-19 vaccine doses.

Pfizer (PFE) Inks Deal With US Government for COVID Jab Supply

Pfizer (PFE) and partner BioNTech (BNTX) enter into an agreement with the government of the United States to supply 105 million doses of its mRNA-based COVID-19 vaccine.

Is Pfizer Stock a Buy Now?

Its vaccine recently obtained Emergency Use Authorization for children as young as six months.

Why I'm Buying Pfizer And You Should Too

Some investors have discounted Pfizer's (NYSE: PFE) future value since the peak of the pandemic is over, but demand for continued development of COVID vaccines for future variants remains strong.

Pfizer Seeks Full FDA Approval For Covid Antiviral Pill Paxlovid

Full approval would allow Pfizer to market the drug to consumers and let it remain on the market when officials declare the Covid emergency over.

Pfizer submits a new NDA to FDA for COVID-19 pill PAXLOVID

Pfizer Inc. PFE, +0.55% said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness. PAXLOVID has p...

Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of PAXLOVID™ (nirmatrelvir [...

U.S. to pay $3.2 billion to Pfizer, BioNTech for more COVID-19 vaccines for fall

Pfizer Inc. PFE, +0.55% and BioNTech SE BNTX, +1.54% said late Wednesday they have inked a new agreement with the U.S. government to supply 105 million doses of their COVID-19 vaccines, including a form...

Other symbols: BNTX

Stocks End Firmly Lower In Yo-Yo Session; Pfizer, Harmony Biosciences, Northrop Grumman In Focus

Sellers also hit Bitcoin, oil, natural gas and gasoline. Get more IBD by subscribing to our channel: https://bit.ly/3OqppAs Visit our website: investors.com Like us on Facebook: https://www.facebook.com...

Other symbols: HRMYNOC

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new vaccine supply agreement with the U.S. government to support the continued fight ...

Other symbols: BNTX

Pfizer (PFE) Discloses Autoimmune Drug Deal With Priovant

Pfizer (PFE) announces the name of the new company that it formed with its partner, Roivant Sciences (ROIV), to develop and market its dual TYK2/JAK1 inhibitor.

FDA recommends updating COVID booster shots to fight Omicron

Yahoo Finance's Anjalee Khemlani joins the Live show to discuss the FDA's vote to update its COVID-19 boosters.

Other symbols: BNTXJNJMRNA

FDA Panel Recommends Modifying COVID Jabs to Target Omicron

The FDA's VRBPAC committee recommends updated COVID-19 vaccine boosters that target the Omicron variant to improve vaccine effectiveness.

Other symbols: BNTXMRNA

Should You Buy, Sell, Or Hold Pfizer Stock At $52?

This marks a significant outperformance compared to some of its peers and the broader markets, with Johnson & Johnson stock rising 16%, Merck stock up 21%, and the S&P 500 index rising just 3% over the ...

FDA advisers recommend Covid fall boosters

CNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on FDA advisers recommendation for covid fall boosters.

Other symbols: BNTXMRNA

Investors Need Not Be Alarmed by Drug Patent Expirations

Investors who are sweating the loss of patent protection for some of Big Pharma's top-selling drugs should relax.